

BREATHTEC BIOMEDICAL INC.

Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Announces Trading on OTCQB

--Company now fully reporting on OTC Markets in America, and continues trading in Canada (CSE) and in Frankfurt (XFRA).

VANCOUVER, BRITISH COLUMBIA -- (Marketwired - May 19, 2016) - [Breathtec Biomedical, Inc.](#) (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that its common shares are now trading on the OTCQB® Venture Market in the United States under the symbol “BTHCF.”

“Breathtec has received international attention regarding our innovative breath testing technologies and recent NA-NOSE technology partnership with the Technion - Israel Institute of Technology. With today’s announcement we have also significantly increased our international visibility in the capital markets,” said Mr. Kal Malhi, President of Breathtec Biomedical. “This is a major step forward as it positions the Company on a proven trading platform with access to a broad segment of the American investment community which builds upon our current exposure to Canadian and European markets. As a result, we are moving ahead and rapidly furthering development of our novel technologies in readiness for what we perceive is a global marketplace opportunity.”

The OTCQB Venture Market is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

Breathtec Biomedical, Inc. will continue to trade on the Canadian Securities Exchange under its existing symbol CSE: BTH, and on the Frankfurt exchange as XFRA: BTI.

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"
President & Director

For further information, please contact:

CORE Capital Partners
Telephone: 604-566-9233
Email: investors@ccpartnersinc.com
Website: www.breathtecbiomedical.com

CAUTIONARY DISCLAIMER STATEMENT: The applicable Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should",

"anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the applicable Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.